Published in Viruses on March 22, 2013
The role of immunophilins in viral infection. Biochim Biophys Acta (2014) 0.80
Structure of FIV capsid C-terminal domain demonstrates lentiviral evasion of genetic fragility by coevolved substitutions. Sci Rep (2016) 0.76
Inhibitors of peptidyl proline isomerases as antivirals in hepatitis C and other viruses. PLoS Pathog (2014) 0.75
Selective Inhibitor of Nuclear Export (SINE) Compounds Alter New World Alphavirus Capsid Localization and Reduce Viral Replication in Mammalian Cells. PLoS Negl Trop Dis (2016) 0.75
The cytoplasmic body component TRIM5alpha restricts HIV-1 infection in Old World monkeys. Nature (2004) 17.56
Cyclophilin: a specific cytosolic binding protein for cyclosporin A. Science (1984) 8.01
Human immunodeficiency virus type 1 Gag protein binds to cyclophilins A and B. Cell (1993) 7.34
Specific incorporation of cyclophilin A into HIV-1 virions. Nature (1994) 7.13
Cyclophilin A retrotransposition into TRIM5 explains owl monkey resistance to HIV-1. Nature (2004) 7.10
Functional association of cyclophilin A with HIV-1 virions. Nature (1994) 6.82
Crystal structure of human cyclophilin A bound to the amino-terminal domain of HIV-1 capsid. Cell (1996) 6.74
Cyclophilin A modulates the sensitivity of HIV-1 to host restriction factors. Nat Med (2003) 5.97
Structure of the amino-terminal core domain of the HIV-1 capsid protein. Science (1996) 5.44
Restriction of multiple divergent retroviruses by Lv1 and Ref1. EMBO J (2003) 4.19
Cyclophilin A is required for an early step in the life cycle of human immunodeficiency virus type 1 before the initiation of reverse transcription. J Virol (1996) 4.15
Characterization of intracellular reverse transcription complexes of human immunodeficiency virus type 1. J Virol (2001) 3.66
Structure of the N-terminal 283-residue fragment of the immature HIV-1 Gag polyprotein. Nat Struct Biol (2002) 3.54
[Determination of enzymatic catalysis for the cis-trans-isomerization of peptide binding in proline-containing peptides]. Biomed Biochim Acta (1984) 2.80
[Cyclosporin A, a Peptide Metabolite from Trichoderma polysporum (Link ex Pers.) Rifai, with a remarkable immunosuppressive activity]. Helv Chim Acta (1976) 2.58
Cyclophilin interactions with incoming human immunodeficiency virus type 1 capsids with opposing effects on infectivity in human cells. J Virol (2005) 2.54
Binding and susceptibility to postentry restriction factors in monkey cells are specified by distinct regions of the human immunodeficiency virus type 1 capsid. J Virol (2004) 2.41
Cyclosporine A-resistant human immunodeficiency virus type 1 mutants demonstrate that Gag encodes the functional target of cyclophilin A. J Virol (1996) 2.39
Species-specific tropism determinants in the human immunodeficiency virus type 1 capsid. J Virol (2004) 2.37
Cyclophilin A, TRIM5, and resistance to human immunodeficiency virus type 1 infection. J Virol (2006) 2.31
The cyclophilin inhibitor Debio-025 shows potent anti-hepatitis C effect in patients coinfected with hepatitis C and human immunodeficiency virus. Hepatology (2008) 2.24
Cyclophilin A is an essential cofactor for hepatitis C virus infection and the principal mediator of cyclosporine resistance in vitro. J Virol (2008) 2.22
Cyclophilin A is required for TRIM5{alpha}-mediated resistance to HIV-1 in Old World monkey cells. Proc Natl Acad Sci U S A (2005) 2.21
Spontaneous mutations in the human immunodeficiency virus type 1 gag gene that affect viral replication in the presence of cyclosporins. J Virol (1996) 2.07
The non-immunosuppressive cyclosporin DEBIO-025 is a potent inhibitor of hepatitis C virus replication in vitro. Hepatology (2006) 1.99
Inhibition of human immunodeficiency virus type 1 replication by SDZ NIM 811, a nonimmunosuppressive cyclosporine analog. Antimicrob Agents Chemother (1994) 1.98
Essential role of cyclophilin A for hepatitis C virus replication and virus production and possible link to polyprotein cleavage kinetics. PLoS Pathog (2009) 1.94
Specific inhibition of hepatitis C virus replication by cyclosporin A. Biochem Biophys Res Commun (2004) 1.93
Suppression of hepatitis C virus replication by cyclosporin a is mediated by blockade of cyclophilins. Gastroenterology (2005) 1.85
The isomerase active site of cyclophilin A is critical for hepatitis C virus replication. J Biol Chem (2009) 1.79
Cyclophilin A and TRIM5alpha independently regulate human immunodeficiency virus type 1 infectivity in human cells. J Virol (2006) 1.77
Crystal structure of human calcineurin complexed with cyclosporin A and human cyclophilin. Proc Natl Acad Sci U S A (2002) 1.75
The cyclophilin inhibitor Debio 025 combined with PEG IFNalpha2a significantly reduces viral load in treatment-naïve hepatitis C patients. Hepatology (2009) 1.75
Human immunodeficiency virus type 1 replication is modulated by host cyclophilin A expression levels. J Virol (1998) 1.73
Crystal structure of calcineurin-cyclophilin-cyclosporin shows common but distinct recognition of immunophilin-drug complexes. Proc Natl Acad Sci U S A (2002) 1.72
Diverse effects of cyclosporine on hepatitis C virus strain replication. J Virol (2006) 1.72
NIM811, a cyclophilin inhibitor, exhibits potent in vitro activity against hepatitis C virus alone or in combination with alpha interferon. Antimicrob Agents Chemother (2006) 1.69
Transfer of the HIV-1 cyclophilin-binding site to simian immunodeficiency virus from Macaca mulatta can confer both cyclosporin sensitivity and cyclosporin dependence. Proc Natl Acad Sci U S A (1997) 1.68
DEB025 (Alisporivir) inhibits hepatitis C virus replication by preventing a cyclophilin A induced cis-trans isomerisation in domain II of NS5A. PLoS One (2010) 1.59
Influence of gag on human immunodeficiency virus type 1 species-specific tropism. J Virol (2004) 1.57
Critical role of cyclophilin A and its prolyl-peptidyl isomerase activity in the structure and function of the hepatitis C virus replication complex. J Virol (2009) 1.50
Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent. Antimicrob Agents Chemother (2008) 1.46
Cyclophilin A: an auxiliary but not necessary cofactor for TRIM5alpha restriction of HIV-1. Virology (2006) 1.45
Naturally occurring capsid substitutions render HIV-1 cyclophilin A independent in human cells and TRIM-cyclophilin-resistant in Owl monkey cells. J Biol Chem (2005) 1.45
HCV resistance to cyclosporin A does not correlate with a resistance of the NS5A-cyclophilin A interaction to cyclophilin inhibitors. J Hepatol (2010) 1.43
Inhibition of human immunodeficiency virus replication by nonimmunosuppressive analogs of cyclosporin A. Proc Natl Acad Sci U S A (1995) 1.42
Altered HIV-1 Gag protein interactions with cyclophilin A (CypA) on the acquisition of H219Q and H219P substitutions in the CypA binding loop. J Biol Chem (2005) 1.38
Immunophilins and the nervous system. Nat Med (1995) 1.34
Trim5alpha accelerates degradation of cytosolic capsid associated with productive HIV-1 entry. J Biol Chem (2006) 1.32
A mutation in alpha helix 3 of CA renders human immunodeficiency virus type 1 cyclosporin A resistant and dependent: rescue by a second-site substitution in a distal region of CA. J Virol (2007) 1.28
The NMR structure of cyclosporin A bound to cyclophilin in aqueous solution. Biochemistry (1991) 1.25
Cyclophilin binds to the region of cyclosporine involved in its immunosuppressive activity. Eur J Immunol (1987) 1.21
Debio 025, a cyclophilin binding molecule, is highly efficient in clearing hepatitis C virus (HCV) replicon-containing cells when used alone or in combination with specifically targeted antiviral therapy for HCV (STAT-C) inhibitors. Antimicrob Agents Chemother (2008) 1.18
Selection for loss of Ref1 activity in human cells releases human immunodeficiency virus type 1 from cyclophilin A dependence during infection. J Virol (2004) 1.14
Differential dependence of the infectivity of HIV-1 group O isolates on the cellular protein cyclophilin A. Virology (2002) 1.11
Safety, pharmacokinetics, and antiviral activity of the cyclophilin inhibitor NIM811 alone or in combination with pegylated interferon in HCV-infected patients receiving 14 days of therapy. Antiviral Res (2011) 1.00
Modulation of HIV-1 infectivity and cyclophilin A-dependence by Gag sequence and target cell type. Retrovirology (2009) 0.94
Cyclophilin inhibitors. Clin Liver Dis (2009) 0.94
Cyclophilin inhibitors in hepatitis C viral infection. Expert Opin Investig Drugs (2007) 0.92
Pharmacology of cyclosporine (sandimmune). I. Introduction. Pharmacol Rev (1990) 0.89
Molecular mechanisms of immunosuppression. J Autoimmun (1992) 0.88
Cyclophilin and viruses: cyclophilin as a cofactor for viral infection and possible anti-viral target. Drug Target Insights (2007) 0.86
An evaluation of the cyclophilin inhibitor Debio 025 and its potential as a treatment for chronic hepatitis C. Expert Opin Investig Drugs (2009) 0.84
Structural basis for the non-immunosuppressive character of the cyclosporin A analogue Debio 025. Biochemistry (2010) 0.84
Cyclosporine and analogues--isolation and synthesis--mechanism of action and structural requirements for pharmacological activity. Fortschr Chem Org Naturst (1986) 0.80
Debio-025 inhibits HIV-1 by interfering with an early event in the replication cycle. Antiviral Res (2009) 0.79
Human immunodeficiency virus type 1, human protein interaction database at NCBI. Nucleic Acids Res (2008) 3.54
Genetic and pharmacologic inhibition of mitochondrial-dependent necrosis attenuates muscular dystrophy. Nat Med (2008) 2.49
The cyclophilin inhibitor Debio-025 shows potent anti-hepatitis C effect in patients coinfected with hepatitis C and human immunodeficiency virus. Hepatology (2008) 2.24
The non-immunosuppressive cyclosporin DEBIO-025 is a potent inhibitor of hepatitis C virus replication in vitro. Hepatology (2006) 1.99
Evaluation of a cyclophilin inhibitor in hepatitis C virus-infected chimeric mice in vivo. Hepatology (2007) 1.95
Molecular evidence of HIV-1 transmission in a criminal case. Proc Natl Acad Sci U S A (2002) 1.92
A novel neutrophil elastase inhibitor prevents elastase activation and surface cleavage of the epithelial sodium channel expressed in Xenopus laevis oocytes. J Biol Chem (2006) 1.75
Development of a comprehensive human immunodeficiency virus type 1 screening algorithm for discovery and preclinical testing of topical microbicides. Antimicrob Agents Chemother (2008) 1.68
Dimer initiation signal of human immunodeficiency virus type 1: its role in partner selection during RNA copackaging and its effects on recombination. J Virol (2007) 1.60
DEB025 (Alisporivir) inhibits hepatitis C virus replication by preventing a cyclophilin A induced cis-trans isomerisation in domain II of NS5A. PLoS One (2010) 1.59
The transmembrane serine protease (TMPRSS3) mutated in deafness DFNB8/10 activates the epithelial sodium channel (ENaC) in vitro. Hum Mol Genet (2002) 1.58
Activation of epithelial sodium channels by mouse channel activating proteases (mCAP) expressed in Xenopus oocytes requires catalytic activity of mCAP3 and mCAP2 but not mCAP1. J Am Soc Nephrol (2006) 1.48
Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent. Antimicrob Agents Chemother (2008) 1.46
Naturally occurring capsid substitutions render HIV-1 cyclophilin A independent in human cells and TRIM-cyclophilin-resistant in Owl monkey cells. J Biol Chem (2005) 1.45
HCV resistance to cyclosporin A does not correlate with a resistance of the NS5A-cyclophilin A interaction to cyclophilin inhibitors. J Hepatol (2010) 1.43
In vitro and in vivo regulation of transepithelial lung alveolar sodium transport by serine proteases. Am J Physiol Lung Cell Mol Physiol (2005) 1.34
Resistance of human cytomegalovirus to the benzimidazole L-ribonucleoside maribavir maps to UL27. J Virol (2003) 1.32
Trim5alpha accelerates degradation of cytosolic capsid associated with productive HIV-1 entry. J Biol Chem (2006) 1.32
The nonimmunosuppressive cyclosporin analogs NIM811 and UNIL025 display nanomolar potencies on permeability transition in brain-derived mitochondria. J Bioenerg Biomembr (2004) 1.27
Moloney leukemia virus 10 (MOV10) protein inhibits retrovirus replication. J Biol Chem (2010) 1.27
A highly conserved arginine in gp120 governs HIV-1 binding to both syndecans and CCR5 via sulfated motifs. J Biol Chem (2005) 1.23
ENaC-mediated alveolar fluid clearance and lung fluid balance depend on the channel-activating protease 1. EMBO Mol Med (2010) 1.20
Inhibition of mitochondrial permeability transition improves functional recovery and reduces mortality following acute myocardial infarction in mice. Am J Physiol Heart Circ Physiol (2007) 1.18
Debio 025, a cyclophilin binding molecule, is highly efficient in clearing hepatitis C virus (HCV) replicon-containing cells when used alone or in combination with specifically targeted antiviral therapy for HCV (STAT-C) inhibitors. Antimicrob Agents Chemother (2008) 1.18
HIV-host interactions: a map of viral perturbation of the host system. AIDS (2009) 1.16
Inhibition of HIV-1 replication by amphotericin B methyl ester: selection for resistant variants. J Biol Chem (2006) 1.11
Cyclosporine increases human immunodeficiency virus type 1 vector transduction of primary mouse cells. J Virol (2006) 1.09
Dimeric RNA recognition regulates HIV-1 genome packaging. PLoS Pathog (2013) 1.07
Albumin-conjugated C34 peptide HIV-1 fusion inhibitor: equipotent to C34 and T-20 in vitro with sustained activity in SCID-hu Thy/Liv mice. J Biol Chem (2008) 1.05
Cyclophilin a plays distinct roles in human immunodeficiency virus type 1 entry and postentry events, as revealed by spinoculation. J Virol (2002) 1.05
Old rhesus macaques treated with interleukin-7 show increased TREC levels and respond well to influenza vaccination. Rejuvenation Res (2007) 1.05
Broad spectrum antimicrobial activity of leukocyte extracts from the American alligator (Alligator mississippiensis). Vet Immunol Immunopathol (2005) 1.01
Cross-reactive HIV-1-neutralizing activity of serum IgG from a rabbit immunized with gp41 fused to IgG1 Fc: possible role of the prolonged half-life of the immunogen. Vaccine (2008) 1.01
Development of indole compounds as small molecule fusion inhibitors targeting HIV-1 glycoprotein-41. J Med Chem (2011) 1.00
Suboptimal inhibition of protease activity in human immunodeficiency virus type 1: effects on virion morphogenesis and RNA maturation. Virology (2008) 0.98
Inhibiting early-stage events in HIV-1 replication by small-molecule targeting of the HIV-1 capsid. J Virol (2012) 0.98
Resistance of human cytomegalovirus to D- and L-ribosyl benzimidazoles as a tool to identify potential targets for antiviral drugs. Nucleosides Nucleotides Nucleic Acids (2003) 0.97
Phosphorylation of beta-D-ribosylbenzimidazoles is not required for activity against human cytomegalovirus. Antimicrob Agents Chemother (2002) 0.94
Inhibition of human cytomegalovirus replication by benzimidazole nucleosides involves three distinct mechanisms. Antimicrob Agents Chemother (2004) 0.93
Cyclophilin inhibitors in hepatitis C viral infection. Expert Opin Investig Drugs (2007) 0.92
Potent strategy to inhibit HIV-1 by binding both gp120 and gp41. Antimicrob Agents Chemother (2010) 0.92
The cyclophilin inhibitor alisporivir prevents hepatitis C virus-mediated mitochondrial dysfunction. Hepatology (2012) 0.91
Potent and broad neutralizing activity of a single chain antibody fragment against cell-free and cell-associated HIV-1. MAbs (2010) 0.91
Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV. Antimicrob Agents Chemother (2010) 0.90
A conditional allele at the mouse channel activating protease 1 (Prss8) gene locus. Genesis (2002) 0.90
Debio-025 is more effective than prednisone in reducing muscular pathology in mdx mice. Neuromuscul Disord (2010) 0.90
Active immunization to tumor necrosis factor-alpha is effective in treating chronic established inflammatory disease: a long-term study in a transgenic model of arthritis. Arthritis Res Ther (2009) 0.89
Development of real-time PCR array for simultaneous detection of eight human blood-borne viral pathogens. PLoS One (2012) 0.88
HSV neutralization by the microbicidal candidate C5A. PLoS One (2011) 0.87
Cyclophilin inhibitors block arterivirus replication by interfering with viral RNA synthesis. J Virol (2012) 0.86
Cyclophilin A-independent recruitment of NS5A and NS5B into hepatitis C virus replication complexes. J Gen Virol (2010) 0.86
Discovery of a small-molecule antiviral targeting the HIV-1 matrix protein. Bioorg Med Chem Lett (2012) 0.85
An evaluation of the cyclophilin inhibitor Debio 025 and its potential as a treatment for chronic hepatitis C. Expert Opin Investig Drugs (2009) 0.84
Structural basis for the non-immunosuppressive character of the cyclosporin A analogue Debio 025. Biochemistry (2010) 0.84
Identification of a small-molecule inhibitor of HIV-1 assembly that targets the phosphatidylinositol (4,5)-bisphosphate binding site of the HIV-1 matrix protein. ChemMedChem (2013) 0.84
A novel anti-HIV active integrase inhibitor with a favorable in vitro cytochrome P450 and uridine 5'-diphospho-glucuronosyltransferase metabolism profile. Antiviral Res (2013) 0.84
Discovery and optimization of novel small-molecule HIV-1 entry inhibitors using field-based virtual screening and bioisosteric replacement. Bioorg Med Chem Lett (2014) 0.84
Mechanisms of human immunodeficiency virus type 2 RNA packaging: efficient trans packaging and selection of RNA copackaging partners. J Virol (2011) 0.83
Structure-activity relationship studies of indole-based compounds as small molecule HIV-1 fusion inhibitors targeting glycoprotein 41. J Med Chem (2014) 0.81
Therapeutic immunization with Modified Vaccinia Virus Ankara (MVA) vaccines in SIV-infected rhesus monkeys undergoing antiretroviral therapy. J Med Primatol (2007) 0.81
Sustained local delivery of structurally diverse HIV-1 microbicides released from sublimation enthalpy controlled matrices. Pharm Res (2012) 0.80
Readily acquired secondary infections of human and simian immunodeficiency viruses following single intravenous exposure in non-human primates. J Gen Virol (2004) 0.80
Structure-activity relationships of a novel capsid targeted inhibitor of HIV-1 replication. J Chem Inf Model (2014) 0.79
Highly potent chimeric inhibitors targeting two steps of HIV cell entry. J Biol Chem (2011) 0.79
Debio-025 inhibits HIV-1 by interfering with an early event in the replication cycle. Antiviral Res (2009) 0.79
Effect of neutrophil elastase and its inhibitor EPI-hNE4 on transepithelial sodium transport across normal and cystic fibrosis human nasal epithelial cells. Respir Res (2010) 0.78
Degradation of Quillaja saponaria Molina saponins: loss of the protective effects of a herpes simplex virus 1 subunit vaccine. Int Immunopharmacol (2002) 0.78
Debio 0932, a new oral Hsp90 inhibitor, alleviates psoriasis in a xenograft transplantation model. Acta Derm Venereol (2014) 0.77
Nucleosides with self-complementary hydrogen-bonding motifs: synthesis and base-pairing studies of two nucleosides containing the imidazo[4,5-d]pyridazine ring system. Bioorg Med Chem (2006) 0.77
Synthesis, antiviral activity, and mode of action of some 3-substituted 2,5,6-trichloroindole 2'- and 5'-deoxyribonucleosides. J Med Chem (2004) 0.76
Evaluation of PD 404,182 as an anti-HIV and anti-herpes simplex virus microbicide. Antimicrob Agents Chemother (2013) 0.75
Synthesis and antiviral activity of 2-substituted analogs of triciribine. Nucleosides Nucleotides Nucleic Acids (2003) 0.75